MELBOURNE, Australia and
SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity
Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the
Company"), will present at the upcoming 7th International Congress
of Multiple System Atrophy (MSA2021), to be held in a virtual
format from February 26-27, 2021.
The event is a world leading conference on Multiple System
Atrophy (MSA), a rapidly progressive and debilitating
neurodegenerative disease without approved treatment. MSA is
characterized by motor symptoms similar to those in Parkinson's
disease and autonomic failure that manifests as impaired ability to
maintain normal blood pressure, bowel and bladder function. MSA2021
promotes international collaboration and the acceleration of
research for MSA treatments. With the event being postponed in 2020
due to COVID-19, this year's congress will be held in a live and
on-demand virtual format.
Alterity's presentation will be featured as part of the
Congress' poster presentations, available online for attendees to
access on demand.
Alterity will be presenting further information on ATH434, its
lead development candidate for the treatment of MSA. The new
results to be presented include data on blood pressure following
change in body position, which demonstrate that ATH434 does not
lower blood pressure when subjects move to the standing position.
This is an important safety finding considering impaired
maintenance of blood pressure is a cardinal problem in MSA, thus
extending the cardiac and overall safety profile previously
presented.
As part of its Phase 2 program, Alterity is also undertaking a
natural history study in collaboration with Vanderbilt University Medical Center, the results
of which will inform the design of the treatment study targeted to
start in 2H '21 .
Commenting on the Company's participation in this year's
congress, Alterity Therapeutics CEO Dr David Stamler remarked that "This
scientific meeting includes the leading MSA researchers from around
the globe, and Alterity is eager to share the emerging clinical
data as we advance our Phase 2 program".
Authorisation &
Additional information
This announcement was authorised by David Stamler, CEO of Alterity Therapeutics
Limited.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/alterity-to-present-at-the-7th-international-congress-of-multiple-system-atrophy-301236319.html
SOURCE Alterity Therapeutics Limited